Triple

T6216916
Position Surface form Disambiguated ID Type / Status
Subject Committee for Medicinal Products for Human Use E139009 entity
Predicate worksWith P398 FINISHED
Object Pharmacovigilance Risk Assessment Committee E130558 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pharmacovigilance Risk Assessment Committee | Statement: [Committee for Medicinal Products for Human Use, worksWith, Pharmacovigilance Risk Assessment Committee]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Pharmacovigilance Risk Assessment Committee
Context triple: [Committee for Medicinal Products for Human Use, worksWith, Pharmacovigilance Risk Assessment Committee]
  • A. Pharmacovigilance Risk Assessment Committee chosen
    The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
  • B. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
    The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
  • C. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • D. Centre for Pharmacovigilance
    The Centre for Pharmacovigilance is a Norwegian public health unit responsible for monitoring, assessing, and improving the safety of medicines and vaccines in Norway.
  • E. Committee for Medicinal Products for Human Use
    The Committee for Medicinal Products for Human Use is the European Medicines Agency’s expert body responsible for evaluating and providing scientific opinions on the safety, quality, and efficacy of medicines for human use in the European Union.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c008aecb0c81909984b48f733ce8ae completed March 22, 2026, 3:20 p.m.
NER Named-entity recognition batch_69c062a1eb3881908c7f735cf9c429ce completed March 22, 2026, 9:44 p.m.
NED1 Entity disambiguation (via context triple) batch_69c20db4e0ac8190ba7bca1f9d8ac6df completed March 24, 2026, 4:06 a.m.
Created at: March 22, 2026, 4:21 p.m.